ProstaLund AB announces today that the Patent and Registration Office (PRV) has announced that it intends to approve the company’s patent application 2150095-4, which concerns a kit consisting of the company’s product Schelin Catheter® together with anesthetic, BOTOX®* or penicillin. The patent number is 544,983 and the patent is valid until 2041. This particular patent family also includes previously granted utility patents in China (in February 2022) as well as pending US applications and an international PCT application that will be completed in at least Europe.
The Schelin Catheter® is a device designed to be used to administer local anesthesia to the prostate. The product is not specially adapted for ProstaLundits own method, CoreTherm®, but is compatible with a variety of methods where local anesthesia of the prostate is needed.
“The granted product patent will be of great value to ProstaLundconsidering that the product will be used outdoors Swedens limits in different areas of use. We have always felt secure in our patent situation, but it means a lot to have it confirmed by PRV. Now that we have had this patent granted, we find ourselves in an even more interesting position in discussions with future potential partners and other stakeholders,” says the CEO. Johan Wennerholm in a comment.
*BOTOX® and its design are registered trademarks Allergan, Inc.an AbbVie company.